NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare Neuromuscular Disorders - Global Genes
Novo Seeds portfolio company NMD Pharma reports positive top-line Phase I/IIa data in myasthenia gravis - Startup Weekly
NMD Pharma A/S | LinkedIn
Jeito Capital Becomes Key Investor in NMD Pharma as Part of a €35 Million New Financing | Business Wire
NMD Pharma vinder pris i vækstkonkurrence | EY Danmark
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma (@NMDPharma) / Twitter
NMD Pharma gets green light to proceed with neuromuscular target — MedWatch
NMD pulls in $40M from Jeito-led, Roche-backed syndicate, gaining financial muscle to crack myasthenia gravis market | Fierce Biotech
NMD Pharma raises €35m to expand pipeline - European Pharmaceutical Manufacturer
Chasing Big Pharma rivals, NMD posts data on rare disease drug
NMD Pharma is about to start a combined Phase I/IIa clinical trial with its ClC-1 channel inhibitor in healthy subjects and patients with myasthenia gravis – ION CHANNEL LIBRARY